Akorn Inc v.

CourtCourt of Appeals for the Third Circuit
DecidedNovember 25, 2022
Docket21-2973
StatusUnpublished

This text of Akorn Inc v. (Akorn Inc v.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Akorn Inc v., (3d Cir. 2022).

Opinion

NOT PRECEDENTIAL

UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT _____________

No. 21-2973 _____________

IN RE: AKORN INC.

AFSCME DISTRICT COUNCIL 47 HEALTH & WELFARE FUND; SERGEANTS BENEVOLENT ASSOCIATION HEALTH AND WELFARE FUND, Appellants ______________

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE (D.C. No. 1-20-cv-01254) District Judge: Honorable Maryellen Noreika ______________

Submitted Under Third Circuit L.A.R. 34.1(a) September 20, 2022

______________

Before: AMBRO, RESTREPO, and FUENTES, Circuit Judges.

(Filed: November 25, 2022) ______________

OPINION* ______________

* This disposition is not an opinion of the full Court and, pursuant to I.O.P. 5.7, does not constitute binding precedent. RESTREPO, Circuit Judge.

This appeal concerns a challenge to the approval of a Chapter 11 bankruptcy plan

(the “Plan”). Appellants are unsecured creditors of Appellee, Akorn, Inc. They raise

several defects in the Plan that they claim left insufficient value to afford their creditor

class a recovery under its waterfall. The Bankruptcy Court approved the Plan and the

District Court affirmed. We will likewise affirm.

I.

We presume the parties’ familiarity with the case and set out only the facts needed

for the discussion below.

The Parties. Appellee Akorn is a pharmaceutical company in the business of

generic and branded health products. Appellants are among plaintiffs to a multidistrict

litigation against Akorn and other generic drug manufacturers for alleged anti-

competitive conduct. In re Generic Pharms. Pricing Antitrust Litig., No. 2:16-MD-2724-

CMR (E.D. Pa. Aug. 5, 2016).

The Merger and Related Pre-Petition Settlement. After a failed merger with

Fresenius Kabi AG in April 2018, Akorn settled related securities litigation with a class

of shareholders in August 2019. In re Akorn, Inc. Data Integrity Secs. Litig., No. 1:18-

CV-1713 (N.D. Ill. Mar. 8, 2018) (the “Class Action Settlement”). Settling plaintiffs,

excluding those who opted out (the “Opt-Out Shareholders”), received a distribution of

2 $27.5 million directly from a D&O insurance carrier and approximately 6.7 million

shares of Akorn common stock.

The Sale. The failed merger and Akorn’s associated financial issues subsequently

affected a loan agreement with Akorn’s secured lenders (the “Secured Lenders”), and a

Standstill Agreement was later reached between the two, allowing Akorn some

“breathing room” to either refinance or pay down its debts. JA385.

The Secured Lenders eventually agreed to serve as a stalking-horse bidder in

Chapter 11, preserving Akorn’s business as a going concern through a “credit bid” on

Akorn’s outstanding debt. JA130. The Secured Lenders subsequently agreed to purchase

the bulk of Akorn’s assets in exchange for a release of Akorn’s debt under the loan

agreement. The Secured Lenders also agreed to assume $5 million of Akorn’s additional

undisputed non-litigation unsecured debt.

Not included in the sale were a remaining D&O insurance policy, hypothetical

avoidance actions to recover the Class Action Settlement, liabilities arising from

litigation against Akorn by Provepharm, and a 50% interest in a defunct nasal spray

product (together, the “Retained Assets”). The Bankruptcy Court approved the sale over

Appellants’ objections, noting that “the market has spoken with respect to the value of

the debtor’s assets,” as “[t]he current offer is the best and only actionable transaction

supported by most parties in interest.” JA589.

The Chapter 11 Plan. Akorn’s reorganization plan included eight classes, with

the Secured Lenders in “Class 3,” and unsecured claimants, like Appellants, in “Class 4.”

Class 3 was designated an “impaired” class, and as such, its approval of the Plan allowed

3 it to proceed, despite objections, as a Bankruptcy Code § 1129(b) “cramdown.” After a

three-day trial, the Bankruptcy Court overruled Appellants’ objections and confirmed the

Plan.

Disposal of the Retained Assets. Each of the remaining Retained Assets was

then strategically disposed of as part of the wind-down process. Post-petition, Akorn

settled with the Opt-Out Shareholders using funds from its remaining D&O insurance

policy, but declined to avoid the Class Action Settlement, citing the cost and uncertainty

of unwinding it. Akorn settled litigation with Provepharm, releasing its counterclaims to

garner Provepharm’s support for the Plan. Similarly, Akorn settled litigation with Rising,

its co-owner in the nasal spray product, in exchange for the rest of its share in the product

and Rising’s support for the Plan.

II.

Appellants raised fifteen errors related to the Plan below; the District Court

rejected all of them. On appeal, Plaintiffs assert that (1) the Retained Assets had value,

and as such, the manner of their distribution under the Plan did not maximize the value of

the estate and violated the absolute priority rule; (2) Akorn should have proceeded

through Chapter 7 instead of Chapter 11; (3) the Plan misclassified creditors and treated

certain classes unfairly; and (4) the Plan was put forth in bad faith.

III.

The District Court had jurisdiction pursuant to 28 U.S.C. § 158(a)(1). We have

jurisdiction pursuant to 28 U.S.C. § 1291.

4 “Because the District Court sat as an appellate court to review the Bankruptcy

Court, we review the Bankruptcy Court’s legal determinations de novo, its factual

findings for clear error, and its exercises of discretion for abuse thereof.” In re Goody's

Family Clothing Inc., 610 F.3d 812, 816 (3d Cir. 2010).1

IV.

We review each of Appellants’ challenges to the Plan in turn.

A. Improper Designation of Retained Assets as Having No Value

Frustrated that they did not recover on their unsecured litigation claims against

Akorn under the Plan, Appellants argue that Akorn’s distribution of the Retained Assets

violated the absolute priority rule and constituted a failure to maximize the value of the

estate available to creditors like themselves.

The absolute priority rule bars transfers of property under a plan to creditors junior

to a claimant class (here an unsecured class), absent the senior class’s consent. 11 U.S.C.

§ 1129(b)(2)(B)(ii). Appellants argue that the Retained Assets were valuable estate

property that should have been used to satisfy their claims and not distributed to junior

creditors. The Bankruptcy Court implicitly and the District Court explicitly rejected this

1 More specifically, the Bankruptcy Court’s findings as to the value of estate property are reviewable for clear error. See In re Fruehauf Trailer Corp., 444 F.3d 203, 214 (3d Cir. 2006). A bankruptcy court’s factual finding “that creditors rejecting the plan would not receive a greater recovery in a Chapter 7 liquidation,” is reviewed for clear error. In re PWS Holding Corp., 228 F.3d, 224, 250 (3d Cir. 2000). Further, this Court “will uphold a plan’s classification scheme so long as it is reasonable and does not arbitrarily designate classes.” In re W.R. Grace & Co.,

Related

Cite This Page — Counsel Stack

Bluebook (online)
Akorn Inc v., Counsel Stack Legal Research, https://law.counselstack.com/opinion/akorn-inc-v-ca3-2022.